Holen Sie sich die Stockscreener-App
26.57
5.44%
-1.53
Handel nachbörslich:
26.57
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Yahoo Finance
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - MarketScreener
Exclusive Look: Avidity Biosciences Reveals Latest Strategy at Needham Healthcare Conference - Stock Titan
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Australia
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - Morningstar
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com India
EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo Finance
New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com
Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia
Citi maintains $70 target on Avidity Biosciences stock post-trial By Investing.com - Investing.com Canada
Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga India
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
Avidity Biosciences reports progress in DMD treatment trial - Investing.com India
Avidity Biosciences Announces Positive EXPLORE44 Trial Results - TipRanks
Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial -March 17, 2025 at 07:12 am EDT - Marketscreener.com
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skip - Financial Times
Bank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
BMO Capital Markets Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The Malaysian Reserve
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth By Investing.com - Investing.com South Africa
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN
Avidity Biosciences chief scientific officer sells $602,614 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Announces Upcoming Presentations at the Musc - GuruFocus.com
Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com India
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):